{"id":"https://openalex.org/W2339819000","doi":"https://doi.org/10.1016/s1473-3099(16)30004-4","title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","display_name":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","publication_year":2016,"publication_date":"2016-04-26","ids":{"openalex":"https://openalex.org/W2339819000","doi":"https://doi.org/10.1016/s1473-3099(16)30004-4","mag":"2339819000","pmid":"https://pubmed.ncbi.nlm.nih.gov/27107460"},"language":"en","primary_location":{"id":"doi:10.1016/s1473-3099(16)30004-4","doi":"https://doi.org/10.1016/s1473-3099(16)30004-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1473-3099(16)30004-4","pdf_url":null,"source":{"id":"https://openalex.org/S23772524","display_name":"The Lancet Infectious Diseases","issn_l":"1473-3099","issn":["1473-3099","1474-4457"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet Infectious Diseases","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2339819000"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023479710","display_name":"Yehuda Carmeli","orcid":"https://orcid.org/0009-0001-9248-2187","observed_orcids":["https://orcid.org/0009-0001-9248-2187"]},"institutions":[{"id":"https://openalex.org/I2799807261","display_name":"Tel Aviv Sourasky Medical Center","ror":"https://ror.org/04nd58p63","country_code":"IL","type":"healthcare","lineage":["https://openalex.org/I2799807261"]}],"countries":["IL"],"is_corresponding":true,"raw_author_name":"Yehuda Carmeli","raw_affiliation_strings":["Division of Epidemiology and the National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Electronic address: yehudac@tlvmc.gov.il","Division of Epidemiology and the National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Epidemiology and the National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Electronic address: yehudac@tlvmc.gov.il","institution_ids":["https://openalex.org/I2799807261"]},{"raw_affiliation_string":"Division of Epidemiology and the National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel","institution_ids":["https://openalex.org/I2799807261"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081263517","display_name":"Jon M. Armstrong","orcid":"https://orcid.org/0009-0008-2292-1835","observed_orcids":["https://orcid.org/0009-0008-2292-1835"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jon Armstrong","raw_affiliation_strings":["AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005775087","display_name":"Peter J. Laud","orcid":"https://orcid.org/0000-0002-3766-7090","observed_orcids":["https://orcid.org/0000-0002-3766-7090"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I91136226","display_name":"University of Sheffield","ror":"https://ror.org/05krs5044","country_code":"GB","type":"education","lineage":["https://openalex.org/I91136226"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Peter J Laud","raw_affiliation_strings":["AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK; Statistical Services Unit, University of Sheffield, Sheffield, UK","AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK","Statistical Services Unit, University of Sheffield, Sheffield, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK; Statistical Services Unit, University of Sheffield, Sheffield, UK","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I91136226"]},{"raw_affiliation_string":"AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK","institution_ids":["https://openalex.org/I105036370"]},{"raw_affiliation_string":"Statistical Services Unit, University of Sheffield, Sheffield, UK","institution_ids":["https://openalex.org/I91136226"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Paul Newell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul Newell","raw_affiliation_strings":["AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020992600","display_name":"Gregory G. Stone","orcid":"https://orcid.org/0000-0001-6115-2567","observed_orcids":["https://orcid.org/0000-0001-6115-2567"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Greg Stone","raw_affiliation_strings":["AstraZeneca, Infection GMed, Global Medicines Development, Waltham, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Infection GMed, Global Medicines Development, Waltham, MA, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039856540","display_name":"Angela Wardman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Angela Wardman","raw_affiliation_strings":["AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Infection GMed, Global Medicines Development, Alderley Park, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084081858","display_name":"Leanne B. Gasink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leanne B Gasink","raw_affiliation_strings":["AstraZeneca, Infection GMed, Global Medicines Development, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Infection GMed, Global Medicines Development, Wilmington, DE, USA","institution_ids":["https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5023479710"],"corresponding_institution_ids":["https://openalex.org/I2799807261"],"apc_list":{"value":7280,"currency":"USD","value_usd":7280},"apc_paid":null,"fwci":24.2041,"has_fulltext":false,"cited_by_count":431,"citation_normalized_percentile":{"value":0.9982888,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"16","issue":"6","first_page":"661","last_page":"673"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":0.9390000104904175,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":0.9390000104904175,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11232","display_name":"Urinary Tract Infections Management","score":0.033399999141693115,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.01979999989271164,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ceftazidime-avibactam","display_name":"ceftazidime-avibactam","score":0.9259999990463257},{"id":"https://openalex.org/keywords/carbapenemase-producing-enterobacterales","display_name":"carbapenemase-producing Enterobacteriaceae","score":0.7739999890327454},{"id":"https://openalex.org/keywords/pseudomonas-aeruginosa","display_name":"Pseudomonas aeruginosa","score":0.9559999704360962},{"id":"https://openalex.org/keywords/complicated-urinary-tract-infection","display_name":"complicated urinary tract infection","score":0.953000009059906},{"id":"https://openalex.org/keywords/complicated-intra-abdominal-infections","display_name":"complicated intra-abdominal infections","score":1.0},{"id":"https://openalex.org/keywords/multidrug-resistant-infections","display_name":"multidrug-resistant infections","score":0.7490000128746033},{"id":"https://openalex.org/keywords/best-available-therapy","display_name":"best available therapy","score":0.7570000290870667},{"id":"https://openalex.org/keywords/clinical-response","display_name":"clinical response","score":0.531000018119812},{"id":"https://openalex.org/keywords/test-of-cure","display_name":"test of cure","score":0.6869999766349792},{"id":"https://openalex.org/keywords/carbapenem-resistance","display_name":"carbapenem resistance","score":0.6460000276565552}],"concepts":[{"id":"https://openalex.org/C2775933652","wikidata":"https://www.wikidata.org/wiki/Q15410251","display_name":"Ceftazidime/avibactam","level":5,"score":0.8928322792053223},{"id":"https://openalex.org/C2776968632","wikidata":"https://www.wikidata.org/wiki/Q808845","display_name":"Ceftazidime","level":4,"score":0.8241746425628662},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7539495825767517},{"id":"https://openalex.org/C2777406300","wikidata":"https://www.wikidata.org/wiki/Q15410251","display_name":"Avibactam","level":5,"score":0.592430591583252},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5448976755142212},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5356044173240662},{"id":"https://openalex.org/C2777637488","wikidata":"https://www.wikidata.org/wiki/Q31856","display_name":"Pseudomonas aeruginosa","level":3,"score":0.4676271080970764},{"id":"https://openalex.org/C77411442","wikidata":"https://www.wikidata.org/wiki/Q181100","display_name":"Urinary system","level":2,"score":0.4399169981479645},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3873109817504883},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.28852272033691406},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.12102332711219788},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002442","descriptor_name":"Ceftazidime","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002442","descriptor_name":"Ceftazidime","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004755","descriptor_name":"Enterobacteriaceae","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006090","descriptor_name":"Gram-Negative Bacteria","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011550","descriptor_name":"Pseudomonas aeruginosa","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000382","qualifier_name":"microbiology","is_major_topic":false},{"descriptor_ui":"D015780","descriptor_name":"Carbapenems","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D024901","descriptor_name":"Drug Resistance, Multiple, Bacterial","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D053961","descriptor_name":"Azabicyclo Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D053961","descriptor_name":"Azabicyclo Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D059413","descriptor_name":"Intraabdominal Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D059413","descriptor_name":"Intraabdominal Infections","qualifier_ui":"Q000382","qualifier_name":"microbiology","is_major_topic":false},{"descriptor_ui":"D065093","descriptor_name":"beta-Lactamase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D065093","descriptor_name":"beta-Lactamase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1016/s1473-3099(16)30004-4","doi":"https://doi.org/10.1016/s1473-3099(16)30004-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1473-3099(16)30004-4","pdf_url":null,"source":{"id":"https://openalex.org/S23772524","display_name":"The Lancet Infectious Diseases","issn_l":"1473-3099","issn":["1473-3099","1474-4457"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet Infectious Diseases","raw_type":"journal-article"},{"id":"pmid:27107460","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27107460","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet. Infectious diseases","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:eprints.whiterose.ac.uk:131152","doi":null,"is_oa":false,"landing_page_url":"http://eprints.whiterose.ac.uk/131152/5/THELANCETID-D-15-01163R1%20REPRISE%20manuscript%20revised%20V2.2.pdf","pdf_url":"http://eprints.whiterose.ac.uk/131152/5/THELANCETID-D-15-01163R1%20REPRISE%20manuscript%20revised%20V2.2.pdf","source":{"id":"https://openalex.org/S4306400854","display_name":"White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2800616092","host_organization_name":"White Rose University Consortium","host_organization_lineage":["https://openalex.org/I2800616092"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W846546774","https://openalex.org/W1502659707","https://openalex.org/W1755049501","https://openalex.org/W1827703416","https://openalex.org/W1968620719","https://openalex.org/W1986439495","https://openalex.org/W2017352107","https://openalex.org/W2026414172","https://openalex.org/W2056317617","https://openalex.org/W2057418340","https://openalex.org/W2103847950","https://openalex.org/W2106578604","https://openalex.org/W2118836068","https://openalex.org/W2151487356","https://openalex.org/W2153512397","https://openalex.org/W2294833633","https://openalex.org/W4248726629"],"related_works":["https://openalex.org/W2339982133","https://openalex.org/W2511572419","https://openalex.org/W2750406710","https://openalex.org/W1859834500","https://openalex.org/W7218399510","https://openalex.org/W2101004558","https://openalex.org/W4405107773","https://openalex.org/W2485810778","https://openalex.org/W2551769634","https://openalex.org/W2437593726"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":25},{"year":2025,"cited_by_count":36},{"year":2024,"cited_by_count":37},{"year":2023,"cited_by_count":39},{"year":2022,"cited_by_count":47},{"year":2021,"cited_by_count":45},{"year":2020,"cited_by_count":50},{"year":2019,"cited_by_count":46},{"year":2018,"cited_by_count":54},{"year":2017,"cited_by_count":27},{"year":2016,"cited_by_count":23},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}